Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
XFOR Stock Summary
Top 10 Correlated ETFs
XFOR
In the News
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.
X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying
X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixafor will likely still have a role in chronic neutropenia as add-on to G-CSF. Mavorixafor can enable reductions in G-CSF dosing, which can improve tolerability and is meaningful for patients. FDA has granted priority review for mavorixafor in WHIM, with a PDUFA date of April 30, 2024, and a potential PRV worth $100M upon approval.
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being held in New York City, from November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference being held in New York City, from November 28-30, 2023.
X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer Christophe Arbet-Engels – Chief Medical Officer Adam Mostafa – Chief Financial Officer Conference Call Participants Eva Privitera – TD Cowen Stephen Willey – Stifel Edward Tenthoff – Piper Sandler Andy Fleszar – B. Riley Securities Kristen Kluska – Cantor Fitzgerald Swayampakula Ramakanth – H.C.
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2023 and providing corporate updates on Thursday, November 9, 2023.
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023.
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the second quarter ended June 30, 2023, and providing corporate and clinical program updates on Thursday, August 10, 2023.
X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa - CFO Mark Baldry - Chief Commercial Officer Conference Call Participants William Wood - B. Riley Securities Eva Privitera - TD Cowen Swayampakula Ramakanth - Wainwright Rick Miller - Cantor Fitzgerald Operator Greetings, and welcome to X4 Pharmaceuticals' First Quarter 2023 Earnings Conference Call.
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023.
X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome study
X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trading higher on Wednesday as investors gear up for new results from a Phase 3 trial of its oral cxcr4 antagonist, mavorixafor, for treatment of patients with WHIM syndrome. The firm will present new data at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St.
XFOR Financial details
XFOR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.15 | 0 | 0 | 0 | |
Net income per share | -4.91 | -3.09 | -3.44 | -1.48 | -0.57 | |
Operating cash flow per share | -4.17 | -2.93 | -2.75 | -1.21 | -0.54 | |
Free cash flow per share | -4.18 | -3 | -2.78 | -1.22 | -0.54 | |
Cash per share | 10.94 | 3.92 | 3.18 | 1.92 | 0.64 | |
Book value per share | 11.21 | 3.63 | 2.5 | 1.17 | 0.29 | |
Tangible book value per share | 8.86 | 2.28 | 1.83 | 0.89 | 0.19 | |
Share holders equity per share | 11.21 | 3.63 | 2.5 | 1.17 | 0.29 | |
Interest debt per share | 2.17 | 2.05 | 1.69 | 0.67 | 0.35 | |
Market cap | 123.37M | 129.1M | 58.97M | 63.08M | 149.1M | |
Enterprise value | 20.1M | 88.84M | 16.96M | -20.22M | 107.91M | |
P/E ratio | -2.18 | -2.08 | -0.66 | -0.67 | -1.47 | |
Price to sales ratio | 0 | 43.03 | 0 | 0 | 0 | |
POCF ratio | -2.57 | -2.19 | -0.83 | -0.82 | -1.54 | |
PFCF ratio | -2.56 | -2.15 | -0.82 | -0.82 | -1.54 | |
P/B Ratio | 0.95 | 1.77 | 0.92 | 0.85 | 2.92 | |
PTB ratio | 0.95 | 1.77 | 0.92 | 0.85 | 2.92 | |
EV to sales | 0 | 29.61 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.46 | -1.48 | -0.26 | 0.23 | -1.02 | |
EV to operating cash flow | -0.42 | -1.51 | -0.24 | 0.26 | -1.12 | |
EV to free cash flow | -0.42 | -1.48 | -0.24 | 0.26 | -1.12 | |
Earnings yield | -0.46 | -0.48 | -1.5 | -1.49 | -0.68 | |
Free cash flow yield | -0.39 | -0.47 | -1.21 | -1.22 | -0.65 | |
Debt to equity | 0.18 | 0.53 | 0.62 | 0.52 | 1.09 | |
Debt to assets | 0.14 | 0.31 | 0.34 | 0.25 | 0.38 | |
Net debt to EBITDA | 2.35 | 0.67 | 0.64 | 0.94 | 0.39 | |
Current ratio | 13.68 | 6.97 | 6.27 | 5.76 | 5.34 | |
Interest coverage | -24.08 | -22.27 | -23.37 | -21.93 | -18.61 | |
Income quality | 0.91 | 0.95 | 0.8 | 0.82 | 0.95 | |
Dividend Yield | 0.16 | 0.1 | 0 | 0 | 0 | |
Payout ratio | -0.35 | -0.2 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 6.98 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 13.98 | 0 | 0 | 0 | |
Intangibles to total assets | 0.17 | 0.22 | 0.15 | 0.11 | 0.12 | |
Capex to operating cash flow | 0 | 0.02 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | -0.45 | 0 | 0 | 0 | |
Capex to depreciation | -1.69 | -3.88 | -1.23 | -0.2 | -0.03 | |
Stock based compensation to revenue | 0 | 1.81 | 0 | 0 | 0 | |
Graham number | 35.18 | 15.89 | 13.92 | 6.23 | 1.92 | |
ROIC | -0.36 | -0.52 | -0.77 | -0.75 | -0.98 | |
Return on tangible assets | -0.42 | -0.65 | -0.89 | -0.68 | -0.78 | |
Graham Net | 8.34 | 1.46 | 1.15 | 0.65 | 0.11 | |
Working capital | 119.83M | 71.36M | 73.86M | 106.35M | 99.21M | |
Tangible asset value | 102.11M | 45.69M | 47.06M | 56.7M | 33.75M | |
Net current asset value | 97.8M | 33.24M | 35.11M | 47.14M | 25.92M | |
Invested capital | 0.18 | 0.53 | 0.62 | 0.52 | 1.09 | |
Average receivables | 2.43M | 1.46M | 832K | 949.5K | 857K | |
Average payables | 1.32M | 2.62M | 3.71M | 6.03M | 8.36M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 111.57 | 0 | 0 | 0 | |
Days payables outstanding | 1.13K | 0 | 826.27 | 1.42K | 1.64K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 3.27 | 0 | 0 | 0 | |
Payables turnover | 0.32 | 0 | 0.44 | 0.26 | 0.22 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.44 | -0.85 | -1.38 | -1.27 | -1.98 | |
Capex per share | -0.02 | -0.07 | -0.02 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.16 | -0.33 | -0.33 | -0.01 | -0.1 | |
Operating cash flow per share | -0.18 | -0.13 | -0.13 | -0.11 | -0.14 | |
Free cash flow per share | -0.18 | -0.13 | -0.13 | -0.11 | -0.14 | |
Cash per share | 0.64 | 0.84 | 0.84 | 0.72 | 0.58 | |
Book value per share | 0.35 | 0.4 | 0.4 | 0.34 | 0.26 | |
Tangible book value per share | 0.24 | 0.3 | 0.3 | 0.26 | 0.17 | |
Share holders equity per share | 0.35 | 0.4 | 0.4 | 0.34 | 0.26 | |
Interest debt per share | 0.26 | 0.23 | 0.23 | 0.3 | 0.29 | |
Market cap | 144.95M | 146.8M | 327.35M | 214.72M | 166.67M | |
Enterprise value | 88.47M | 47.25M | 227.8M | 141.42M | 125.48M | |
P/E ratio | -1.51 | -0.66 | -1.47 | -23.29 | -2.18 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -5.47 | -6.85 | -15.28 | -10.31 | -6.01 | |
PFCF ratio | -5.47 | -6.85 | -15.27 | -10.31 | -6 | |
P/B Ratio | 2.8 | 2.17 | 4.85 | 3.18 | 3.26 | |
PTB ratio | 2.8 | 2.17 | 4.85 | 3.18 | 3.26 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.02 | -1.83 | -8.83 | -5.5 | -4.99 | |
EV to operating cash flow | -3.34 | -2.21 | -10.63 | -6.79 | -4.52 | |
EV to free cash flow | -3.34 | -2.2 | -10.63 | -6.79 | -4.52 | |
Earnings yield | -0.17 | -0.38 | -0.17 | -0.01 | -0.11 | |
Free cash flow yield | -0.18 | -0.15 | -0.07 | -0.1 | -0.17 | |
Debt to equity | 0.71 | 0.55 | 0.55 | 0.86 | 1.09 | |
Debt to assets | 0.3 | 0.21 | 0.21 | 0.34 | 0.38 | |
Net debt to EBITDA | 1.93 | 3.86 | 3.86 | 2.85 | 1.64 | |
Current ratio | 5.04 | 6.64 | 6.64 | 5.81 | 5.34 | |
Interest coverage | -20.66 | -22.48 | -22.48 | -16.65 | -13.36 | |
Income quality | 1.1 | 0.38 | 0.38 | 9.04 | 1.45 | |
Dividend Yield | 0 | 0.5 | 0 | 0 | 0 | |
Payout ratio | 0 | -1.32 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.14 | 0.1 | 0.1 | 0.1 | 0.12 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.07 | -0.06 | -0.06 | -0.08 | -0.56 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.14 | 1.72 | 1.72 | 0.3 | 0.75 | |
ROIC | -0.25 | -0.24 | -0.24 | -0.21 | -0.23 | |
Return on tangible assets | -0.22 | -0.36 | -0.36 | -0.01 | -0.15 | |
Graham Net | 0.15 | 0.21 | 0.21 | 0.18 | 0.09 | |
Working capital | 78.74M | 125.4M | 125.4M | 122.44M | 99.21M | |
Tangible asset value | 34.33M | 50.18M | 50.18M | 50.24M | 33.75M | |
Net current asset value | 25.49M | 41.79M | 41.79M | 42.17M | 25.92M | |
Invested capital | 0.71 | 0.55 | 0.55 | 0.86 | 1.09 | |
Average receivables | 905K | 739K | 820K | 606.5K | 477.5K | |
Average payables | 6.88M | 5.55M | 5.11M | 6.62M | 8.54M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.08K | 897.89 | 890.93 | 1.46K | 12.99K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.08 | 0.1 | 0.1 | 0.06 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.46 | -0.82 | -0.82 | -0.03 | -0.37 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
XFOR Frequently Asked Questions
What is X4 Pharmaceuticals, Inc. stock symbol ?
X4 Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol XFOR
Is X4 Pharmaceuticals, Inc. buy or a sell ?